JHJan Harder

Jan Harder

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jan Harder has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • ID-Proteine beim Hepatozellulären Karzinom: Expression und prognostische Bedeutung

    by Mj Fuchs, A Schmitt-Graeff, J Hasskarl, V Gumpp, Og Opitz, J Harder

    Einleitung: Die ID-Proteine (inhibitor of DNA-binding/differentiation), welche zur Gruppe der basic Helix-Loop-Helix Proteine (bHLH) gehören, wurden in verschiedenen Neoplasien, wie z.B. dem Kolon-, Pankreas- und Gallenwegskarzion in veränderter Expression im Vergleich zum gesunden Gewebe nachgewiesen. Mehrere Untersuchungen deuten auf die funktionelle Bedeutung der ID-Proteine bei der Tumorentstehung und Progression hin. Ziele: In dieser Studie wurde die Expression aller vier ID-Proteine im Hepatozellulären Karzinom (HCC) und die Korrelation dieser mit klinisch-pathologischen Parametern untersucht. Methodik: Sowohl die nukläre als auch die zytoplasmatische Expression des ID1-, ID2-, ID3- und ID4-Proteins wurden an 145 Tumorproben von Patienten mit HCC und 13 gesunden Kontrollen immunhistochemisch untersucht. Die Expression wurde mit unterschiedlichen klinisch-pathologischen Parametern, wie dem Gesamtüberleben, Alter, MELD-Score, intrahepatischer Metastasierung, AFP und histologischem Grading korreliert. Ergebnis: Für alle vier ID-Proteine wurde im HCC im Vergleich zu den Kontrollen ein differentes Expressionsmuster gefunden. Die zytoplasmatische Expression von ID1, ID2 und ID3 korrelierte signifikant mit einem längerem Gesamtüberleben (p=0,013; p=0,018; bzw. p=0,005). Dagegen konnte für die nukläre Expression von ID4 eine hoch signifikante inverse Korrelation mit dem Gesamtüberleben gezeigt werden (p=0,001). Ebenfalls korrelierte die nukläre ID2, ID3 und ID4 Expression mit einem erhöhten MELD-Score. Die zytoplasmatische ID1-Expression wiederum wies einen signifikanten inversen Zusammenhang mit der intrahepatischen Metastasierung auf. Keine signifikanten Korrelationen der ID-Expression bestand mit den übrigen o.g. Parametern. Schlussfolgerung: Zusammenfassend konnte eine differente Expression aller vier ID-Proteine im HCC im Vergleich zu Kontrollen gefunden werden. Den ID-Proteinen konnte, mit besonderer Beobachtung der subzellulären Lokalisation, eine wahrscheinliche Bedeutung bei der Hepatokarzinogenese nachgewiesen werden. ID1, ID2, ID3 und ID4 wurden als Prognoseparameter beim HCC identifiziert.

  • Trastuzumab and capecitabine in patients with HER2-expressing metastatic pancreatic cancer: A multicenter phase II study of the German AIO Pancreatic Cancer Group (AIO PK-0204).

    by M. Geissler, R. Hofheinz, M. H. Moehler, M. Bitzer, S. H. Boeck, A. Reinacher-Schick, V. Heinemann, J. Harder

    4070 Background: In metastatic pancreatic cancer (mPaCa) overexpression of the HER2 receptor has been reported in up to 82% of cases, suggesting its use as a therapeutic target. Therefore, the study was conducted to determine the efficacy and toxicity of capecitabine (CAP) and trastuzumab (TRAS) in pts with mPaCa. Methods: Eligible pts had histologically confirmed mPaCa. The primary endpoint was PFS at 12 weeks. Pts with mPaCa immunohistochemically overexpressing HER2 grade 3 or grade 2 with gene amplification (FISH) received TRAS 4 mg/kg initially followed by weekly 2 mg/kg combined with CAP 1,250 mg/m2 bid day 1-14, q21. The study with planned 37 pts was prematurely closed due to unexpected low HER2 expression. Results: Between May 1994 and February 1998 a total of 212 pts with a median age 64 years (range 38-86) were centrally screened for HER2 expression. In 207 pts the tumor specimens could be assessed for HER2 expression and gene amplification: By IHC 83 (40%) were grade 0, 71 (34%) grade 1, 31 (15%) grade 2, and 22 (11%) grade 3, respectively. One IHC grade 2 and all IHC grade 3 specimens showed gene amplification by FISH. From the 23 pts with HER2 gene amplification 17 could be assessed for response to treatment and toxicity in an intention- to treat analysis. Reported grade 3/4 toxicities in 88 cycles of chemotherapy were: leucopenia 6%, diarrhea 6%, nausea 6%, hand-foot syndrome 6%. There was no TRAS-attributable cardiac toxicity. PFS at 12 weeks was 23,5%, the median OS was 7.0 months. Conclusions: In contrast to previous findings, this multi-center study demonstrated HER2 overexpression and gene amplification in only 11% of pts with mPaCa. This discrepancy can be explained by the use of centrally reviewed standardized HER2 test methods and the examination of a large unselected cohort in the present study. Although the therapy was well tolerated, PFS and OS did not perform favourably compared to standard gemcitabine chemotherapy even if considering the exclusion of locally advanced PaCa in this cohort. Due to the low HER2 overexpression found in this study we do not recommend further evaluation of anti-HER2 treatment in pts with mPaCa.

  • Inhibition of differentiaton protein expression in advanced Biliary Tract Cancer

    by J Harder, M Müller, J Hasskarl, V Gumpp, He Blum, A Schmitt-Graeff, Og Opitz

    Purpose: Inhibition of differentiation (ID) proteins are helix-loop-helix transcription factors, which are involved in the carcinogenesis of various tumors. For ID protein expression there are no data on biliary tract cancer (BTC) so far. Methods: We analyzed the expression of ID proteins 1–4 in 120 patients with advanced BTC and in 9 controls by immunohistochemistry (IHC). The expression data were correlated with clinicopathological variables in order to determine the relevance of the ID proteins in BTC. The IHC results were categorized into four groups for cytoplasmic (negative, weak, moderate, strong) and for nuclear staining (0–10%; 11–50%, 51–80% and 81–100% of 100 counted cells), respectively. Results: The study cohort comprised 58 (48.3%) women and 62 (51.7%) men with a mean age of 63.5 years (range 32–84). In 39 patients the cholangiocarcinoma was extrahepatic (EHCC), in 48 patients intrahepatic (IHCC) and 33 patients had gallbladder cancer (GBCC). Patients with EHCC had a significantly better overall survival (OS) than patients with IHCC or GBCC (p=0.002). Healthy controls showed only a weak expression of ID proteins 1–3 expression while a significant overexpression of ID proteins 1–3 could be demonstrated in 68.2% (nuclear ID1), 77.5% (cytoplasmic ID2) and 68.3% (nuclear ID3) of BTC. There was no correlation between the expression of ID protein 1–4, tumor grading or BTC subtype. In patients who were not treated by chemotherapy (n=56) there was a significant correlation between nuclear ID protein 1 overexpression and a reduced OS (p=0.001) while for the whole study population it was borderline statistically significant (p=0.057). In the group of patients who received chemotherapy (n=64) absent nuclear ID protein 2 expression was associated with a longer OS (p=0.001). Conclusions: ID proteins 1–3 were significantly overexpressed in advanced BTC. Further, the overexpression of ID protein 1 is prognostic for shorter OS in patients not treated by chemotherapy. In patients treated by chemotherapy absent nuclear 2 expression is a strong prognotic marker for better OS. These data suggest that ID proteins play a role in the carcinogenesis of BTC. The usefulness of ID proteins as prognostic biomarkers should now to be evaluated prospectively.

  • Transarterial chemoembolization of intrahepatic cholangiocarinoma with irinotecan-eluting beads: preliminary results

    by J Harder, W Euringer, M Langer, He Blum, Hc Spangenberg

    Purpose: Patients with unresectable cholangiocarcinoma have a poor prognosis with no standard systemic chemotherapy being established so far. According to recent publications patients with intrahepatic cholangiocarcinoma even respond to chemotherapy to a lesser extent than patients with extrahepatic choangiocarcinoma. Therefore, we performed a pilot study to evaluate the feasibility, safety, and efficacy of transarterial chemoembolization with drug-eluting beads (DEB-TACE) in patients with intrahepatic cholangiocarcinoma. Methods: Thirteen patients (7 female, 6 male) with unresectable intrahepatic cholangiocarcinoma and without evidence of extrahepatic tumor manifestation, aged 48 to 76 years (mean 66 years), underwent 21 sessions of DEB-TACE loaded with 200mg irinotecan between November 2007 and December 2008. Prior to DEB-TACE 7 patients (54%) had progressive disease and 2 (16%) had untolerable side effects under systemic chemotherapy, 3 patients (23%) had contraindications to and 1 (8%) patient refused systemic chemotherapy. Progression free survival was evaluated in 8 weeks intervals after therapy with computed tomography (CT) or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST). Clinical and laboratory data were assessed for side effects according to NCI-CTC. Results: All 21 sessions of DEB-TACE were safely performed with no serious complications. 4 patients (31%) reported of heavy (grade 3) and 6 (46%) of moderate (grade 1 and 2) pain in the right upper abdomen up to two weeks after treatment. No haematological side effects or impairment of liver function tests (≥ grade 3) were observed. The median follow-up was 11 months (range, 4–16 months). Sixteen weeks after TACE, one patient (7%) had a partial response and was treated by liver resection, 8 of 13 patients (62%) had stable and 4 of 13 patients (31%) had progessive disease according to intention to treat analysis. Eight patients have no tumor progression so far with a mean progression free survival of 8.6 months. Conclusions: DEB-TACE with irinotecan is well tolerated and appears effective in patients with intrahepatic CCC. Even in patients pretreated with systemic chemotherapy DEB-TACE can lead to long lasting responses.

  • Open Access

    A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer

    by Andre Mihaljevic, Peter Büchler, Jan Harder, Ralf Hofheinz, Michael Gregor, Stephan Kanzler, Wolff Schmiegel, Volker Heinemann, Esther Endlicher, Günter Klöppel, et al.

    Background: Pancreatic cancer is the fourth most common cause of cancer related death in Western countries. Advantages in surgical techniques, radiation and chemotherapy had almost no impact on the long term survival of affected patients. Therefore, the need for better treatment strategies is urgent. HER2, a receptor tyrosine kinase of the EGFR family, involved in signal transduction pathways leading to cell growth and differentiation is overexpressed in a number of cancers, including breast and pancreatic cancer. While in breast cancer HER2 has already been successfully used as a treatment target, there are only limited data evaluating the effects of inhibiting HER2 tyrosine kinases in patients with pancreatic cancer. Methods: Here we report the design of a prospective, non-randomized multi-centered Phase II clinical study evaluating the effects of the Fluoropyrimidine-carbamate Capecitabine (Xeloda ®) and the monoclonal anti-HER2 antibody Trastuzumab (Herceptin®) in patients with non-resectable, HER2 overexpressing pancreatic cancer. Patients eligible for the study will receive Trastuzumab infusions on day 1, 8 and 15 concomitant to the oral intake of Capecitabine from day 1 to day 14 of each three week cylce. Cycles will be repeated until tumor progression. A total of 37 patients will be enrolled with an interim analysis after 23 patients. Discussion: Primary end point of the study is to determine the progression free survival after 12 weeks of bimodal treatment with the chemotherapeutic agent Capecitabine and the anti-HER2 antibody Trastuzumab. Secondary end points include patient's survival, toxicity analysis, quality of life, the correlation of HER2 overexpression and clinical response to Trastuzumab treatment and, finally, the correlation of CA19-9 plasma levels and progression free intervals.


  • Methylation of the Estrogen receptor promoter in the development of gastric cancer

    by M. Varbanova, J. Harder, V. Engelstaedter, H. Usadel, M. Werner, H. E. Blum, A. Zur Hausen, O. G. Opitz

    Introduction: Gastric carcinogenesis is a multistep process including mutation of different genes but also epigenetic events as aberrant promoter methylation leading to gene silencing. Morphologically, disease progression appears as a sequence of intestinal metaplasia-dysplasia-invasive carcinoma, triggered by Helicobacter pylori infection. Methylation of the Estrogen receptor (ER) promoter has been attributed to the development of colorectal cancer and esophageal adenocarcinoma. The role in gastric carcinogenesis remained elusive. Methods: To study Estrogen receptor promoter methylation by quantitative methylation specific PCR (MSP) we examined gastric mucosa from 49 individuals who underwent an endocopy due to pain of the upper abdomen, from 8 cases with intestinal metaplasia and from 30 individuals with gastric cancer. PCR specimens were analyzed in a blinded fashion and later correlated with histopathological findings. Results: From the 49 individuals examined, 27 had histologically normal gastric mucosa (13/49) or mild Helicobacter pylori negative gastritis (14/49). Three specimens in this population showed positive MSP results (11%). On the other hand all of the 22 individuals with H. pylori positive gastritis showed ER promoter methylation (100%). Furthermore, the 8 specimens from gastric intestinal metaplasia and 30 samples from gastric cancer tested positive for ER promoter methylation. The correlation of ER promoter methylation with H. pylori gastritis, intestinal metaplasia and gastric carcinoma was highly significant. Discussion: ER promoter methylation has been reported in the context of esophageal and colon carcinogenesis. Here we show that this epigenetic event is not tumor specific but is also present in risk conditions for the development of gastric cancer i.e. H.p. infection, suggesting that ER promoter methylation might play a role in the early steps of gastric carcinogenesis and possibly can identify individuals at risk for this highly prevalent tumor.

  • Hypothyroidism in patients with hepatocellular carcinoma treated by transarterial chemoembolization

    by J. Harder, F. Flohr, J. Seufert, H. E. Blum, H. C. Spangenberg

    Introduction: Transarterial chemoembolization (TACE) is the standard of care for patients with an intermediate or advanced stage of hepatocellular carcinoma (HCC) and compensated liver cirrhosis. The procedure involves the application of approx. 10g of iodide in the form of iodized oil as radiopaque contrast medium, e.g. lipiodol, mixed with a chemotherapeutic agent. While contrast medium induced hyperthyroidism is well known, the development of hypothyroidism is generally not considered in clinical practice. This phenomenon is called Wolff Chaikoff effect and is caused by iodide induced inhibition of thyroid hormone synthesis. It is rarely observed after the administration of water-soluble iodinated radiographic contrast media but should be considered after application of lipid-soluble iodinated contrast media. To date there is very little information regarding the incidence of thyroid dysfunction in patients treated with TACE. Methods: We, therefore, retrospectively analyzed a cohort of 219 patients with histologically proven HCC who were treated with TACE at our institution between 1997 and 2007. The patients had a mean age of 66 years; 88% were males. The causes of liver disease were chonic hepatitis C in 32%, chronic hepatitis B in 20% and alcohol in 36%; in 12% other or no etiologies could be identified. From 138/219 patients TSH levels before and after TACE were available. Results: In 23/138 patients (16.7%) TSH suppression was observed after TACE. Among them, 4 patients developed clinical hyperthyroidism requiring medical therapy; 19 patients developed subclinical hyperthyroidism. In 19/138 patients (13.8%) TSH levels increased from a mean before TACE of 3.08µU/ml to a mean of 22.45µU/ml after TACE [range 4.59–76.66µU/ml]. While 6 patients showed a transient hypothyroidism with spontaneous normalization of TSH within 3.2 months, 7 patients were lost to follow-up and 6 patients developed clinical hypothyroidism that required substitution therapy. Discussion: In conclusion, we found a clinically relevant incidence of thyroid dysfunction after TACE, incl. hypothyroidism. In clinical practice, therefore, patients treated with TACE should be monitored not only for the development of hyperthyroidism but also of hypothyroidism.

  • Open Access

    Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer

    by J Harder, B Riecken, O Kummer, C Lohrmann, F Otto, H Usadel, M Geissler, O Opitz, H Henß

    This phase II study was conducted to determine the efficacy and toxicity of a gemcitabine (GEM) and oxaliplatin (OX) chemotherapy protocol in patients with unresectable biliary tract cancer (BTC). Patients were treated with GEM 1000 mg m−2 (30 min infusion) on days 1, 8, 15, and OX 100 mg m−2 (2 h infusion) on days 1 and 15 (gemcitabine and oxaliplatin (GEMOX-3 protocol), repeated every 28 days. The data were collected according to the Simon 2-stage design for a single centre phase II study (α=0.05; β=0.2). Primary end point was response rate; secondary end points were time-to-progression (TTP), median survival, and safety profile. Thirty-one patients were enrolled in the study between July 2002 and April 2005. Therapeutic responses were as follows: partial response in eight patients (26%, 95% confidence interval (CI) 14–44), stable disease in 14 patients (45%, 95%CI 29–62), resulting in a disease control rate of 71%. Nine patients (29%, 95%CI 16–47) had progressive disease. Median TTP was 6.5 months. Median overall survival was 11 months. Common Toxicity Criteria (CTC) Grade 3–4 toxicities were transient thrombocytopenia (23%), peripheral sensory neuropathy (19%), leucopenia (16%), and anaemia (10%). In conclusion the GEMOX-3 protocol is active and well tolerated in patients with advanced BTC. It can be applied in an outpatient setting with three visits per month only.


  • Alternative Verfahren zur chirurgischen Resektion - Lokoregionäre Therapie von Lebermetastasen

    by L. Mohr, H.-C. Spangenberg, J. Harder, H. E. Blum

    Lebermetastasen sind mit großem Abstand die häufigsten malignen Lebertumoren. Die chirurgische Resektion ist heute noch der Goldstandard zur Behandlung solitärer Lebermetastasen kolorektaler Karzinome (CRC), wobei die Fünf-Jahres-Überlebensrate etwa 30 % beträgt. Neben den Fortschritten auf dem Gebiet der Leberchirurgie haben sich in den letzten Jahren auch neue Techniken zur interventionellen Destruktion (Lokalablation) von Tumoren entwickelt, etwa thermische Verfahren wie die Radiofrequenz-Thermoablation (RFTA) und die laserinduzierte Thermotherapie (LITT) oder die perkutane Alkoholinjektion (PEI). Obwohl kontrollierte Studien fehlen, weisen die publizierten Fallserien auf einen positiven Effekt der Lokalablation durch RFTA oder LITT hin. Die transarterielle Chemoembolisation (TACE) zielt auf eine temporäre Embolisation tumorversorgender Gefäße, verursacht eine Hypoxie im Tumorgewebe und verhindert das rasche Ausschwemmen des Chemotherapeutikums. Das Verfahren eignet sich vor allem für die Behandlung hypervaskularisierter Tumoren wie zum Beispiel des multilokulären hepatozellulären Karzinoms (HCC), während die Mehrzahl der Lebermetastasen eher hypovaskularisiert sind. Zu den lokaltherapeutischen Ansätzen zählen auch die strahlentherapeutischen Verfahren, bei denen 131Jod-Lipiodol oder 90Yttrium-Mikrosphären eingesetzt werden, die sich nach transarterieller Applikation bevorzugt im Tumorkapillargebiet festsetzen und dort zu einer hohen lokalen Strahlendosis führen können. Ferner werden lokale perkutane Strahlentherapieverfahren evaluiert. The liver is the most common site for tumour metastastases that are generally associated with a poor prognosis. However, in patients with isolated liver metastases of colorectal cancer (CRC) surgical resection results in a five-year survival of approximately 30 %. In addition to the improvement of liver surgery novel techniques for the local destruction (ablation) of liver tumors were developed such as radiofrequency thermal ablation (RFTA), laser induced thermal therapy (LITT) or percutaneous ethanol injection (PEI). PEI and RFTA are well established treatment options for small hepatocellular carcinomas (HCC), but for the treatment of liver metastases no controlled clinical trials have been performed up to now. However, the published clinical observations suggest, that patients may benefit from local tumor control induced by RFTA or LITT. For transarterial chemoembolization (TACE) a mixture of lipiodol and a chemotherapeutic agent is injected into the hepatic artery or into a tumor-feeding artery followed by temporary embolization. This results in prolonged exposure to the chemotherapeutic drug and in direct tumor damage by hypoxia. TACE is a successful treatment option in HCC, but for metastatic disease only hypervascularized tumors such as renal cell carcinomas or neuroendocrine tumors seem to respond favourably. The transarterial route can also be used for the injection of lipiodol-131iodine or 90yttrium microspheres. These microspheres accumulate predominantly in the tumor vasculature resulting in a high local dose of irradiation. Further, percutaneous radiation therapy is being clinically evaluated.

  • Open Access

    Hepatitis C virus infection in intravenous drug users

    by J. Harder, E. Walter, B. Riecken, C. Ihling, T. M. Bauer